Loading clinical trials...
Loading clinical trials...
A PHASE 1, OPEN-LABEL, RANDOMIZED, 2-WAY CROSSOVER STUDY ON THE EFFECTS OF CC-99677 ON THE PHARMACOKINETICS OF AN ORAL CONTRACEPTIVE IN HEALTHY FEMALE SUBJECTS
Conditions
Interventions
Oral Contraceptive (Ortho Tri-Cyclen or its generic equivalent)
CC-99677
Locations
3
United States
Qps-Mra, Llc
Miami, Florida, United States
Hassman Research Institute
Marlton, New Jersey, United States
PPD Phase 1 Clinic
Austin, Texas, United States
Start Date
September 30, 2020
Primary Completion Date
August 3, 2021
Completion Date
August 3, 2021
Last Updated
October 28, 2021
NCT00104325
NCT07118891
NCT01399385
NCT07295717
NCT03807401
NCT07271693
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions